Literature DB >> 10556567

Draculin, the anticoagulant factor in vampire bat saliva, is a tight-binding, noncompetitive inhibitor of activated factor X.

A Z Fernandez1, A Tablante, S Beguín, H C Hemker, R Apitz-Castro.   

Abstract

The kinetic mechanism of action of Draculin on activated Factor X (FXa) is established. Draculin inhibits activated Factor X within seconds of incubation at near equimolar concentration (2-6 times on molar basis). Fitting the data to the equation for a tight-binding inhibitor gives a value for K(i)(K(d)) = 14.8+/-1.5 nM. The formation of the Draculin-FXa complex can be explained by a two-step mechanism, where for the first, reversible step, k(on) = 1.117 (+/- 0.169, S.E.M.) x 10(6) M(-1)s(-1) and k(off) = 15.388 (+/- 1.672) x 10(-3) s(-1), while for the second, irreversible step, which is concentration-independent, k(2) = 0.072 s(-1). K(d) obtained from k(off)/k(on) = 13.76 nM. Lineweaver-Burk plot shows a noncompetitive behavior. This noncompetitive mode of inhibition of Draculin is supported by the observation that Draculin, at concentrations giving complete inhibition, does not impair binding of p-aminobenzamidine to FXa. Moreover, under the same conditions, Draculin induces <14% decrease of the fluorescence intensity of the p-aminobenzamidine-FXa complex. We conclude that Draculin is a noncompetitive, tight-binding inhibitor of FXa, a characteristic so far unique amongst natural FXa inhibitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556567     DOI: 10.1016/s0167-4838(99)00160-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Desmoteplase: discovery, insights and opportunities for ischaemic stroke.

Authors:  Robert L Medcalf
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

2.  The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1).

Authors:  Christopher J Farady; Jeonghoon Sun; Molly R Darragh; Susan M Miller; Charles S Craik
Journal:  J Mol Biol       Date:  2007-04-04       Impact factor: 5.469

3.  The "Vampirome": Transcriptome and proteome analysis of the principal and accessory submaxillary glands of the vampire bat Desmodus rotundus, a vector of human rabies.

Authors:  Ivo M B Francischetti; Teresa C F Assumpção; Dongying Ma; Yuan Li; Eliane C Vicente; Wilson Uieda; José M C Ribeiro
Journal:  J Proteomics       Date:  2013-02-11       Impact factor: 4.044

4.  Vampire Venom: Vasodilatory Mechanisms of Vampire Bat (Desmodus rotundus) Blood Feeding.

Authors:  Rahini Kakumanu; Wayne C Hodgson; Ravina Ravi; Alejandro Alagon; Richard J Harris; Andreas Brust; Paul F Alewood; Barbara K Kemp-Harper; Bryan G Fry
Journal:  Toxins (Basel)       Date:  2019-01-08       Impact factor: 4.546

5.  An inhibitor of leukotriene-A4 hydrolase from bat salivary glands facilitates virus infection.

Authors:  Mingqian Fang; Xiaopeng Tang; Juan Zhang; Zhiyi Liao; Gan Wang; Ruomei Cheng; Zhiye Zhang; Hongwen Zhao; Jing Wang; Zhaoxia Tan; Peter Muiruri Kamau; Qiumin Lu; Qi Liu; Guohong Deng; Ren Lai
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-01       Impact factor: 12.779

6.  Interaction of the synthetic antithrombotic peptide P10 with thrombin: a spectroscopy study.

Authors:  Fangyuan Chen; Han Jiang; Wenwei Chen; Guangrong Huang
Journal:  RSC Adv       Date:  2019-06-11       Impact factor: 4.036

7.  A Novel Factor Xa-Inhibiting Peptide from Centipedes Venom.

Authors:  Yi Kong; Yu Shao; Hao Chen; Xin Ming; Jin-Bin Wang; Zhi-Yu Li; Ji-Fu Wei
Journal:  Int J Pept Res Ther       Date:  2013-06-19       Impact factor: 1.931

8.  Towards Development of an Anti-Vampire Bat Vaccine for Rabies Management: Inoculation of Vampire Bat Saliva Induces Immune-Mediated Resistance.

Authors:  Horacio A Delpietro; Roberto G Russo; Charles E Rupprecht; Gabriela L Delpietro
Journal:  Viruses       Date:  2021-03-20       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.